Key result
Rivaroxaban monotherapy significantly reduced the duration of hospital stay by a mean of 1.8 days compared to standard therapy in Chinese patients with acute pulmonary embolism.
Why the study?
Does rivaroxaban mono-therapy reduce the duration of hospital stay and improve treatment satisfaction compared to standard therapy in Chinese patients with acute pulmonary embolism?
Observational (n=72)
Single-blind
No
Does rivaroxaban mono-therapy reduce the duration of hospital stay and improve treatment satisfaction compared to standard therapy in Chinese patients with acute pulmonary embolism?
Mean Difference: -1.8 (95% CI -2.9–-0.9)
Absolute Event Rate: 10.2% vs 12%
p-value: p=0.04
In Chinese patients with acute pulmonary embolism, rivaroxaban monotherapy was associated with a shorter hospital stay, higher treatment satisfaction, and less mild bleeding compared to standard enoxaparin and warfarin therapy.
Rivaroxaban may benefit Chinese patients with acute PE; leaves open need for prospective RCTs before changing practice.
Pulmonary embolism (PE) is a life-threatening disease, which accounts for the major type of venous thromboembolism. Currently, there is limited understanding and management for PE. Rivaroxaban is reported to treat patients with PE. However, there is still insufficient evidence on rivaroxaban for the treatment of Chinese patients with acute PE. Thus, this retrospective study investigated the benefits and safety of rivaroxaban for Chinese patients with acute PE.A total of 72 Chinese patient cases with acute PE were analyzed in this study. Of these, 36 cases who received rivaroxaban mono-therapy were assigned to the treatment group, while the remaining 36 cases who received standard therapy were assigned to the control group. The benefits were assessed by the duration of hospital stay, treatment satisfaction, and safety.After treatment, rivaroxaban mono-therapy showed better benefits in decreasing the duration of hospital stay (P < .01), increasing treatment satisfaction (P < .01), and reducing mild bleeding (P = .02) in Chinese patients with acute PE, than standard therapy.The results of this study indicated that rivaroxaban may provide more benefits than the standard therapy for Chinese patients with acute PE. Future studies are still needed to warrant the current results.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2021) conducted an observational in Acute pulmonary embolism (n=72). Rivaroxaban vs. Standard therapy (enoxaparin overlapping with warfarin) was evaluated on Duration of hospital stay (MD -1.8, 95% CI -2.9 to -0.9, p=0.04). Rivaroxaban monotherapy significantly reduced the duration of hospital stay by a mean of 1.8 days compared to standard therapy in Chinese patients with acute pulmonary embolism.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: